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Macrophage colony stimulating factor involvement in uremic patients.
The immunodeficiency of patients with chronic renal failure (CRF) is
related to multiple and complex alterations of the cytokine network and of
its target cells such as T or B lymphocytes, monocytes, fibroblasts or
endothelial cells. Chronic activation of monocytic functions is recognized
as a key factor in these immunological disorders. Since macrophage colony
stimulating factor (M-CSF) is essential for the activation of several
functions of monocytes and macrophages and their production of cyto-
kines such as interleukin-1, interleukin-6, and tumor necrosis factor o, we
investigated its involvement in patients with CRF. When measured by
ELISA, M-CSF serum levels were significantly higher in patients with
progressive CRF and those on hemodialysis (HD) and continuous ambu-
latory peritoneal dialysis (CAPD) than in controls. M-CSF serum levels
did not correlate with the degree of renal insufficiency and were probably
related to complex alterations in its production and/or degradation by the
specific M-CSF receptors of macrophages. In HD patients the M-CSF
serum concentrations inversely correlated with the number of circulating
lymphocytes and were significantly higher in anemic patients requiring
treatment with erythropoietin. Our results suggest that M-CSF may play a
role in altering the immune system in uremic patients by maintaining in
the circulation and tissues permanently primed monocytes and/or macro-
phages that can then be triggered to an activated state by secondary stimuli
such as endotoxins, complement components, other cytokines or contact
with foreign surfaces.
Immunodeficiency is a well known consequence of chronic
renal failure (CRF) that is not corrected by hemodialysis (HD) or
Continuous ambulatory peritoneal dialysis (CAPD) [1]. It is
responsible for increased morbidity and mortality related to a high
incidence of infection and malignant tumors [2, 3].
This immunodeficient state is characterized by multiple and
complex defects in both cellular and humoral defense mecha-
nisms. Abnormal functional responses of granulocytes, mono-
cytes, and T and B lymphocytes have been reported [4—6].
Lymphopenia, depressed mitogenic lymphocyte response, in-
creased suppressor cell activity, and monocytic inhibition of T-cell
proliferation are considered by most authors as key factors in the
immunological alterations of patients with CRF [5, 7—101. By
contrast, both T lymphocytes and monocytes exhibit phenotypic
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and functional signs of permanent activation in uremic patients
[11, 121. This apparent paradox could be partly explained by
recent results reporting multiple imbalances in the "cytokine
networks" of CRF patients with or without dialysis [12]. Overpro-
duction by mononuclear cells and increased circulating levels of
interleukin-1 (IL-i), tumor necrosis factor alpha (TNFa), inter-
leukin-6 (IL-6), interleukin-2 receptor (IL-2R), interleukin-1 re-
ceptor antagonist (IL-i Ra) or TNFs receptors have been de-
scribed [5, 12, 13]. Uremia probably plays a major role in altering
the production of cytokines and impairing monocytic dependent
T-cell proliferation [5, 12, 13].
Macrophage colony stimulating factor (M-CSF or CSF-1) stim-
ulates the survival, proliferation, and differentiation of progenitor
cells of the monocyte-macrophage lineage and activates several
functions of mature macrophages such as tumoricidal or anti-
infectious activities [reviewed in 14]. M-CSF also induces the
production of several cytokines such as IL-i, TNFw, granulocyte-
macrophage colony stimulating factor (GM-CSF) and IL-6 [14,
15]. Fibroblasts, endothelial cells, monocytes and macrophages,
and activated T or B cells produce M-CSF either spontaneously or
after induction by chemical or physiological stimuli [14, 16, 171.
M-CSF can be measured in normal serum or plasma, urine,
various biological fluids, culture supernatants or cell and tissue
extracts by bioassays, radioimmunoassays or enzyme immunoas-
says [14, 181. High M-CSF serum and/or tissue concentrations
were found in several types of immunological, tumoral or infec-
tious processes as well as during normal pregnancy, a situation
with complex physiological modifications of the immune system
[14, 19—21]. While encoded by a unique gene located on chromo-
some 1, alternative splicing of exon 6, combined with various sites
and types of glycosylation generate three different biologically
active M-CSF glycoproteins of 200 kDa (proteoglycan anchored in
stromas), 90 kDa (soluble molecule representing 85% of the
circulating M-CSF), and 45 kDa to 60 kDa (membranous form,
representing 15% of the circulating M-CSF) [14, 22].
Recently, we and others reported increased serum M-CSF
concentrations in HD patients 123—251. The aims of the present
work were: (1) to confirm these results by studying a larger
number of patients with CRF (subjects not requiring dialysis or
those on HD or CAPD), (2) to demonstrate that the high serum
M-CSF concentrations were mainly due to alterations in its
synthesis and/or degradation linked to the multiple disorders of
uremia and not only to reduced renal excretion, (3) to study the
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relationship between lymphocytes, other blood cell counts or
neopterin serum levels on the one hand and M-CSF on the other.
Methods
Patients
A total of 142patients with CRF were included in the study and
gave informed consent; 48 patients did not require dialysis (nD),
71 were on HD and 23 were on CAPD. The etiology of CRF in nD
patients (29 men and 19 women aged 22 to 88, mean 67 13,
serum creatinine level ranging from 125 to 825 j.tmol/liter) is
summarized in Table 1. The creatinine clearance in these nD
patients was calculated using the Cockroft formula (clearance
ranging from 3 to 72 mI/mm, mean 20 15 mI/mm). The HD
patients (37 men and 34 women, aged 12 to 83, mean 60 17) had
undergone HD (3 times per week) for at least six months prior to
the study, using the same membrane and the same dialysis
procedure for at least three months: polyactylonitrile membranes
AN 69 (Hospal, France, 8 patients), Cuprophan (Fresenius,
Germany, 14 patients), Hemophan (Gambro, Sweden, 17 pa-
tients), cellulose diacetate (Hospal, France, 24 patients), poly-
amide (Gambro, Sweden, 8 patients). The CAPD patients (8
women and 15 men aged 35 to 84, mean 64 11) were dialyzed
with a silicone elastomere Tenckhoff catheter for at least six
months prior to the study with four 2-liter bags per day. Fifty-four
healthy blood donors (20 men and 34 women aged 24 to 55, mean
41 7) were used as controls.
Samples
All serum and urine samples obtained from patients without an
infectious process were stored at —20°C. In all nD and CAPD
patients, blood was obtained by venipuncture. In all HD patients,
blood was drawn from the arterial fistula needle just prior to the
routine HD session; in 38 patients blood was drawn during two
different HD sessions performed in the same conditions at a time
interval of 5 to 450 days (mean 205 102); in 20 patients serum
samples were collected before and at the end of the same dialysis
session; in 6 patients arterial and venous samples were serially
collected (just before and at 1 hr and 4 hr of the dialysis
procedure). A blood cell count and differential was obtained in all
patients.
Dosages of M-CSF in serum, urine and molecular weight
separated serum fractions
Dosages of M-CSF were performed using an immunoassay
procedure (ELISA) developed in our laboratory with a polyclonal
rabbit anti-M-CSF antibody that we produced [181. Briefly, 96
wells plates (Maxisorb®; Nunc, Roskilde, Denmark) were coated
for 12 hours with 100 d of a purified anti-M-CSF IgG solution (10
,ig/ml) and saturated for four hours with BSA (5 mg/ml; Sigma,
o (54) nD (48) HD (71) CAPD (23)
168±71 463±212 450±186 538±241
Fig. 1. M-CSF serum concentrations in CRF patients and in controls. Individ-
ual data were obtained in duplicate by an EtA procedure as described in the
Methods section. Numbers between parentheses represent the numbers of
patients in each group. Results represent the mean SD of controls (C),
non-dialyzed patients with CRF (nD), hemodialyzed patients (HD), and
patients on continuous ambulatory peritoneal dialysis (CAPD).
St. Louis, MO, USA) before use. Samples of pure urine or serum
diluted 1:4 and serial dilutions of standard M-CSF (500 to 7 U/mI,
first international M-CSF standard preparation: 60,000 lU/mi,
code 891512; NIBSC, Potters Bar, Hertfordshire, UK) were
distributed (100 l per well) in duplicate. After a 24 hours
incubation at 4°C, the plates were washed. One hundred microli-
ters of biotynilated anti-M-CSF antibodies (1 rg/ml), prepared
from the same batch of anti-M-CSF IgG, were then added to each
well for 24 hours at 4°C. The plates were then washed and
incubated for one hour with avidine phosphatase (Amersham,
Buckinghamshire, UK) before being rinsed. The chromogenic
substrate (Sigma, St. Louis, USA) was finally added, and the
colorimetric reaction stopped after 10 to 15 minutes by adding
NaOH 1 M before reading the optical density of the individual
wells at 405 nm on a microplate reader (Multiskan Plus, Lab-
system). The lower detection limit of the assay is 10 U/mi. Serum
samples from 5 HD patients were loaded and centrifuged (2000 x
g during 2 hr) on ultrafiltration devices (Linda Manufacturing
Corp., Kenosha, US) having different molecular weight cut-off
(respectively 5,000, 10,000, 20,000, 30,000, and 100,000). Ultrafil-
trates were harvested and tested for the presence of immunore-
active M-CSF by ELISA.
Neopterin dosages
We used a commercially available ELISA kit (IBL, Hamburg,
Germany) according to the manufacturer's instructions.
Statistical analysis
All the results were expressed as means SD. Student's unpaired
and paired t-tests were used when appropriate to compare data.
Differences were considered to be significant when P < 0.05.
Results
Serum concentrations of M-CSF
A significant three-fold increase in M-CSF serum concentra-
tions was found (P < 0.01) in nD, HD, and CAPD patients as
Table 1. Etiology of CRF in nHD patients (number of patients)
Chronic glomerulonephritis (11)
Vascular nephropathy (4)
Nephroangiosclerosis (5)
Diabetic glomerulopathy (7)
Polycystic kidney disease (5)
Chronic interstitial nephritis (9)
Immunological disease (3)
Undetermined nephropathy (4)
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Fig. 2. Relationship between M-CSFsenim concentration determined before
two different hemodialysis sessions (M-CSF I and M-CSF 2). The dosages
were performed by EIA in 38 patients at intervals from 5 to 450 days and
compared using regression analysis. r = 0.78; P < 0.001.
compared with controls (Fig. 1). No significant differences were
observed between these three groups of patients.
In the 48 nD patients the M-CSF serum concentrations did not
correlate with the degree of CRF as calculated by the Cockroft
formula (r = 0.08, P > 0.05) and they were not significantly
different regardless of the mechanism and the etiology of their
renal disease (data not shown).
When measured at two different HD sessions (time interval of
5 to 450 days, mean 205 102) in 38 patients, the M-CSF serum
concentrations were not significantly different (dosage 1,458 71
U/mi; dosage 2, 447 182 U/mi) and were even highly correlated
as shown by regression analysis (Fig. 2).
We also tested the potential role of different types of dialysis
membranes on the M-CSF concentrations of HD patients and
found no significant differences between the groups (Table 2).
When tested in 5 HD patients (M-CSF serum concentration
602 70 U/mI, ranging 476 to 660 U/mi), no immunoreactive low
molecular weight degradation products were detected in ultrafil-
tered serum fractions having a molecular weight lower than 30,000
(M-CSF < 4U/ml by ELISA). By contrast, the filtration rate
(M-CSF in the ultrafiltered serum fraction/M-CSF in the retained
serum fraction) through the 100,000 molecular weight filtration
membrane represented 32 5%.
M-CSF serum concentrations during dialysis
The serum concentration of M-CSF significantly increased (P <
0.05) in 20 patients from 390 131 U/mi to 475 96 U/mi during
the four-hour HD session (Fig. 3). This increase was probably due
mainly to hcmoconcentration during the HD session because it
disappeared if the post-HD serum M-CSF concentration was
corrected according to the percentage of increase in serum
protein concentration during the HD session.
In six patients, M-CSF concentrations of the arterial and venous
lines were measured during the HD session at one hour and four
hours. No significant differences were observed between arterial
and venous M-CSF levels (data not shown).
Correlation of M-CSF serum concentrations with hematological
parameters in HD patients
Blood cell counts and differentials were performed in 67 HD
patients at the beginning of a dialysis session. Mean levels SD of
Tab'e 2. Comparison of M-CSF serum concentrations (U/mi) in
patients dialyzed with different types of membranes
Membranes Cuprophan Diacetate Hemophan Polyamide PAN
Serum M-CSF 468 198 409 196 436 199 451 150 468 198
U/mi
Number of 14 24 17 8 8
patients
hemoglobin (Hb), platelets, white blood cells (WBC), monocytes
and lymphocytes are shown in Table 3.
The number of circulating monocytes, platelets or WBC (which
were in the normal range) did not correlate with the M-CSF
serum concentration. Interestingly, a significant inverse relation-
ship was found with the number of circulating lymphocytes (r =
—0.28, P < 0.01) (Fig. 4).
No correlation was found with the quantitative erythropoietin
(Epo) requirements in anemic HD patients permanently treated
with recombinant Epo. However, the mean M-CSF serum con-
centration was found to be significantly different between HD
patients with or without Epo therapy (494 227 U/mi from 85
dosages in 52 treated patients, 395 122 U/mi from 33 dosages in
19 untreated patients, P < 0.01).
Urinaty M-CSF concentrations
The mean urinary M-CSF concentration in 42 patients with
undialyzed CRF was 54 31 U/mI, very similar to the urinary
concentration in controls. Twenty-four hour urine samples were
measured in 20 nD patients and the daily urinary M-CSF excre-
tion (104,000 58,000 U/24 hr) was also very similar to controls.
All these patients had high M-CSF serum levels and no correla-
tion was found between the urinary M-CSF excretion and its
serum concentration or the creatinine clearance (data not shown).
Furthermore, no correlation was found between the urinary
M-CSF concentration and the level of proteinuria (proteinuria
ranging from 20 to 7800 mg per day, r = 0.019, P > 0.05).
Comparison of M-CSF and Neopterin levels in nonhemodialyzed
and hemodialyzed patients
Serum neopterin levels increased in 37 hemodialyzed patients
(114 56 nmol/liter, range 25 to 270; controls < 5 nmol/liter).
and did not correlate with M-CSF serum concentrations (r =
0.075). In nD patients the serum neopterin level was inversely
correlated with the creatinine clearance (r =
—0.66, P < 0.001)
hut not with the M-CSF serum concentration (r = 0.1458, P ;>
0.05). After adjustment of neopterin on creatinine clearance
levels (by calculating the ratio neopterin serum level/creatinirie
clearance) this parameter did not either correlate with M-CSF
serum concentrations (r = 0.17, P> 0.05).
Discussion
In this study we detected an important increase (>3 times) in
M-CSF serum concentrations in a large number of CRF patients
(predialysis or requiring dialysis), as recently reported in smaller
groups of patients by ourselves and others [23—25]. By using an
ultrafiltration procedure we showed that the immunoreactivity
detected in our ELISA is not due to low molecular weight
degradation products. As we also have evidence that biologically
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inactive degraded M-CSF is not detected in our ELISA (data not
shown), it can be assumed that high levels of immunoreactive
M-CSF in CRF patients represents a bioactive M-CSF.
Dosage of serum and urine M-CSF concentrations in 42 nD
patients with varying degrees of CRF showed that their M-CSF
serum concentration did not correlate with the creatinine clear-
ance and that their daily urinary excretion was similar to controls.
Thus, our findings do not agree with those of Sato, Ohkubo and
Nagaoka [24], who assumed that impaired renal metabolism or
excretion of circulating M-CSF was largely responsible for the
increased serum levels. Their conclusion also contradicted other
previously published results which stated that: (1) M-CSF is
totally cleared from the circulation (half life 10 mm) and degraded
into biologically and immunologically inactive metabolites by the
M-CSF receptors of hepatic and splenic macrophages [26, 271; (2)
the kidney excretes mainly inactive degradation products, urinary
M-CSF representing less than 1% of its total daily metabolism
estimated by calculation [26, 27]; (3) urinary M-CSF principally
consists of the 85 kDa glycoprotein molecule, a molecular weight
exceeding the physiological renal ultrafiltration cut-off [28, 29].
Moreover, even in patients with increased proteinuria due to
either glomerular or tubular damage we did not find correlation
between the urinary M-CSF concentration and the level of
proteinuria. Together these data suggest that urinary M-CSF is
produced principally in the urinary tract and that the high M-CSF
serum levels in CRF patients are mainly a consequence of uremia,
Hb
g/100 ml
Platelets
><109/liter
WBC
x 109/liter
Monocytes
X109/liter
Lymphocytes
X109/liter
9.6 1.5 238 85 6.5 2.0 0.52 0.23 1.4 0.52
Post-HD as already shown for other cytokines and cytokine receptors [5, 7,
_j 12, 13].
Overproduction of M-CSF by activated monocytes, activated T
cells, fibroblasts and endothelial cells could increase the M-CSF
serum levels in CRF patients, as shown in other inflammatory
processes [reviewed in 141. Alternatively or concomitantly, M-
CSF receptors could be either down-modulated by their ligand or
down-regulated by various inflammatory mediators, cytokines, or
metabolic by-products that are increased in CRF such as TNFa or
bacterial lipopolysaccharides (LPS) [30, 31].
M-CSF either alone or combined with others cytokines or
biomolecules activates essential functions of macrophages both in
vitro and in vivo [14]. Permanently elevated concentrations of
M-CSF in CRF patients and especially in HD patients could then
synergize with other cytokines such as IL-i, IL-6, or TNFa [12,
13], with biomolecules such as endotoxins and complement com-
ponents [32, 33] and with the phenomena of direct contact of
monocytes with the dialysis membranes [34] to generate "activat-
ed macrophages" that play a pivotal role in the immunodeficiency
of CRF patients.
Not surprisingly we found no correlation between neopterin
and M-CSF serum levels. M-CSF may represent a more accurate
marker of monocyte activation than neopterin in uremic patients
for two reasons: (1) the serum concentration of neopterin (mo-
lecular wt 250 Da), which is dependent on the degree of mac-
rophagic activation in patients without CRF, is essentially depen-
dent on the degree of CRF and/or the HD procedure in uremic
patients [12, 35]; (2) we found that the M-CSF serum concentra-
tions were unrelated to the HD procedure or the quality of the
membrane and did not vary with time. Similar to Sato et al [24],
we demonstrated significantly increased M-CSF serum concentra-
tions after the four-hour HD session that disappeared after
correction for the elevated serum protein level. Since the biolog-
ical activity of a cytokine is dependent on its local concentration
and not of its total amount, increasing serum levels of M-CSF
Table 3. Hematological parameters from 67 HD patients
Results are expressed as mean 5D
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Fig. 3. Variation of semm M-CSF concentrations during a four-hour dialysis
session. Dosage of M-CSF was performed in 20 patients just before
(pre-HD) and at the end (post-HD) of the HD session.
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Fig. 4. Relationship between M-CSF semm concentration and circulating
lymphocytes. M-CSF and lymphocytes were performed together in 116
individuals samples from 67 HD patients and studied using regression
analysis. r = 0.28; P < 0.01.
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during the four-hour HD session also noticed by Sato et at [24]
could participate to the alteration of macrophagic function and
cytokine production observed in the hours following the HD
session [6, 10, 36—38].
Lymphopenia is well known in CRF and especially in HD
patients. It has been observed in normal rats and monkeys
receiving high doses of M-CSF [39, 40]. In HD patients, we found
an inverse relationship between low lymphocytes counts and
increased serum M-CSF concentrations suggesting that M-CSF
plays a role in the lymphopenia of patients with CRF.
Kawano et at [23] previously showed in uremic patients with
anemia that treatment with Epo was less effective when pretreat-
ment M-CSF serum levels were elevated. Since most of our
patients were already under treatment with Epo, this analysis was
impossible. However, in HD patients, we noted a significant
difference in M-CSF serum levels between patients that were or
were not treated with Epo, in agreement with the conclusion of
Kawano et a! [23]. Since monocytes from patients with CRF
produce factors that inhibit the production of Epo in vitro [41],
M-CSF could activate a similar phenomenon in vivo contributing
to the anemia in uremic patients.
In this study, we clearly showed that elevated M-CSF concen-
trations in patients with CRF did not correlate with renal function
and were probably related to the metabolic alterations of uremia.
M-CSF most likely plays a major role in the chronic activation of
monocytes which in turn causes multiple metabolic, hematologic
and immunologic abnormalities in patients with CRF. The cell
types and mechanisms responsible for altered M-CSF metabolism
remain to be elucidated, as well as their role in the macrophagic
activation and immunodeficiency in patients with CRF.
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